Palo Alto Is Leading the Nasdaq Higher, but 1 Biotech Is Getting Crushed WednesdayThe Motley Fool • 02/23/22
Kodiak Sciences stock loses more than three-quarters of its value after disappointing drug trial resultsMarket Watch • 02/23/22
Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular DegenerationPRNewsWire • 02/23/22
Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This QuarterSeeking Alpha • 02/15/22
Kodiak (KOD) Completes Enrolling Patients in Retina-Based StudiesZacks Investment Research • 02/04/22
Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular EdemaPRNewsWire • 02/03/22
Kodiak Sciences (KOD) Focuses on Developing Eye Candidate KSI-301Zacks Investment Research • 12/30/21
Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein OcclusionPRNewsWire • 12/16/21
Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business HighlightsPRNewsWire • 11/09/21
Kodiak Sciences Inc. (KOD) Up 15.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/08/21
Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare ConferencePRNewsWire • 08/31/21
Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business HighlightsPRNewsWire • 08/09/21
Kodiak Sciences Has Declined $125M Funding From Baker Bros Citing Strong Balance SheetBenzinga • 07/23/21
Why Is Kodiak Sciences Inc. (KOD) Down 4% Since Last Earnings Report?Zacks Investment Research • 06/09/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Kodiak Sciences Inc. - KODPRNewsWire • 05/18/21